First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw(Dana-Farber Cancer Institute), Benjamin Solomon(Peter MacCallum Cancer Centre), Yasushi Goto(Tennessee Oncology), Todd M. Bauer(Tennessee Oncology), Anna Maria Calella(Pfizer (United States)), Julien Mazières(Université Toulouse III - Paul Sabatier), Tony Mok(Chinese University of Hong Kong), Gerson Peltz(Tennessee Oncology), Anna Polli(Pfizer (Italy)), Enriqueta Felip(Institut Català d'Ornitologia), Dong‐Wan Kim(Seoul National University Hospital), Filippo de Marinis(Carlo Forlanini Hospital), Geoffrey Liu(Princess Margaret Cancer Centre), Holger Thurm(Pfizer (United States))
Cited by 1,060
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k